Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inaxaplin (VX-147) Phase 2/3 study in APOL1-mediated proteinuric kidney disease
2024-515633-15-00Phase 3Authorised
- Sponsor
- Vertex Pharmaceuticals
- Start
- Oct 2022
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 3, randomised, double-blind trial in APOL1-mediated kidney disease (AMKD) comparing Inaxaplin with Placebo (2 arms). Primary endpoints: Percent change in urine protein-to-creatinine ratio from baseline at Week 48, Estimated glomerular filtration rate slope and 1 more. Planned start Oct 2022; status: authorised.
02
Drugs
inaxaplin
03
Conditions
APOL1-mediated kidney disease (AMKD)
Beyond the preview
Go deeper on 2024-515633-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515633-15-00.